Loading...
Market
What will be the EU's decision on Bavarian Nordic's mpox vaccine for adolescents by the end of 2024?
2
Resolution / Starting Odds
Approved without conditions • 25%
Approved with conditions • 25%
Not approved • 25%
Decision delayed • 25%
European Medicines Agency (EMA) official announcements
Story
Bavarian Nordic Seeks EU Approval for Adolescent Mpox Vaccine
Aug 16, 2024, 07:30 AM
Danish biotech company Bavarian Nordic has submitted data to the European Union's drug regulator seeking approval to extend the use of its mpox vaccine to adolescents. Bavarian Nordic is currently the only company with a vaccine approved for mpox in both the United States and Europe. The company aims to expand the vaccine's usage to a younger demographic, highlighting its ongoing efforts to enhance public health measures against mpox.
View original story
Similar markets
Approved by Q3 2024 • 25%
Approved by Q4 2024 • 25%
Approved by Q1 2025 • 25%
Not approved by Q1 2025 • 25%
Increases by more than 10% • 25%
Increases by 5-10% • 25%
Increases by less than 5% • 25%
Decreases or remains the same • 25%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
United States • 25%
European Union • 25%
Africa • 25%
Other • 25%
Less than 1 million • 25%
1 to 3 million • 25%
3 to 5 million • 25%
More than 5 million • 25%
Approved without conditions • 25%
Approved with conditions • 25%
Rejected • 25%
Pending decision • 25%
